Cost-benefit analysis of pharmacist interventions over 36 months in a university hospital
DOI:
https://doi.org/10.11606/s1518-8787.2020054001895Keywords:
Cost-Benefit Analysis, Pharmacy Service, Hospital. Economics, Pharmaceutical, Pharmaceutical ServicesAbstract
OBJECTIVE: To perform a cost-benefits analysis of a clinical pharmacy (CP) service implemented in a Neurology ward of a tertiary teaching hospital. METHODS: This is a cost-benefit analysis of a single arm, prospective cohort study performed at the adult Neurology Unit over 36 months, which has evaluated the results of a CP service from a hospital and Public Health System (PHS) perspective. The interventions were classified into 14 categories and the costs identified as direct medical costs. The results were analyzed by the total and marginal cost, the benefit-cost ratio (BCR) and the net benefit (NB). RESULTS: The total 334 patients were followed-up and the highest occurrence in 506 interventions was drug introduction (29.0%). The marginal cost for the hospital and avoided cost for PHS was US$182±32 and US$25,536±4,923 per year; and US$0.55 and US$76.4 per patient/year. The BCR and NB were 0.0, -US$26,105 (95%CI -31,850 – -10,610), -US$27,112 (95%CI -33,160–11,720) for the hospital and; 3.0 (95%CI 1.97–4.94), US$51,048 (95%CI 27,645–75,716) and, 4.6 (95%CI 2.24–10.05), US$91,496 (95%CI 34,700–168,050; p < 0.001) for the PHS, both considering adhered and total interventions, respectively. CONCLUSIONS: The CP service was not directly cost-benefit at the hospital perspective, but it presented savings for forecast cost related to the occurrence of preventable morbidities, measuring a good cost-benefit for the PHS.
References
Welty TE. Neurology and neurosurgery clinical pharmacy practice: ignorance, phobia or progress? Ann Pharmacother. 2006;40(12):2235-7. https://doi.org/10.1345/aph.1H495
Yi ZM, Sun SS, Li XX, Lu M, Zhai SD. An evaluation of clinical pharmacist service on a neurology care unit. Int J Clin Pharm. 2016;38:30-3. https://doi.org/10.1007/s11096-015-0224-y
Winterstein AG, Sauer BC, Hepler CD, Poole C. Preventable drug-related hospital admissions. Ann Pharmacother. 2002;36(7-8):1238-48. https://doi.org/10.1345/aph.1A225
Mergenhagen KA, Blum SS, Kugler A, Livote EE, Nebeker JR, Ott MC, et al. Pharmacist- versus physician-initiated admission medication reconciliation: impact on adverse drug events. Am J Geriatr Pharmacother. 2012;10(4):242-50. https://doi.org/10.1016/j.amjopharm.2012.06.001
Howard RL,Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol. 2007;63(2):136-47. https://doi.org/10.1111/j.1365-2125.2006.02698.x
Sekhar MS, Adheena Mary C, Anju PG, Hamsa NA. Study on drug related admissions in a tertiary care hospital in South India. Saudi Pharm J. 2011;19(4):273-8. https://doi.org/10.1016/j.jsps.2011.04.004
Williams M, Peterson GM, Tenni PC, Bindoff IK, Stafford AC. DOCUMENT: a system for classifying drug-related problems in community pharmacy. Int J Clin Pharm.2012;34(1):43-52. https://doi.org/10.1007/s11096-011-9583-1
Gillespie U, Alassaad A, Henrohn D, Garmo H, Hammarlund-Udenaes M, Toss H, et al. A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older. Arch Intern Med. 2009;169(9):894-900. https://doi.org/10.1001/archinternmed.2009.71
Vieira FS. Produção de informação de custos para a tomada de decisão no Sistema Único de Saúde: uma questão para a política pública. Rio de Janeiro: Instituto de Pesquisa Econômica Aplicada - IPEA; 2017 [cited 2018 Jan 15]. (Texto para Discussão, 2314). Available from: http://www.ipea.gov.br/portal/images/stories/PDFs/TDs/td_2314.pdf
Ministério da Saúde (BR), Departamento de Informática do SUS. Database. Brasília, DF: DATASUS; 2018 [cited 2018 Jul 25]. Available from: www2.datasus.gov.br/DATASUS/index.php?area=01
Hanson RL, Habibi M, Khamo N, Abdou S, Stubbings J. Integrated clinical and specialty pharmacy practice model for management of patients with multiple sclerosis. Am J Health Syst Pharm. 2014;71(6):463-9. https://doi.org/10.2146/ajhp130495
Rodrigues JPV, Marques FA, Gonçalves AMRF, Campos MSA, Reis TM, Morelo MRS, et al. Analysis of clinical pharmacist interventions in the Neurology Unit of a Brazilian tertiary teaching hospital. PLoS One. 2019;14(1):e0210779. https://doi:10.1371/journal.pone.0210779
Foppa AA, Chemello C, Vargas-Peláez CM, Farias MR. Medication therapy management service for patients with Parkinson’s disease: a before-and-after study. Neurol Ther. 2016;5(1):85-99. https://doi.org/10.1007/s40120-016-0046-4
Kopp BJ, Mrsan M, Erstad BL, Duby JJ. Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. Am J Health Syst Pharm. 2007;64(23):2483-7. https://doi.org/10.2146/ajhp060674
Touchette DR, Doloresco F, Suda KJ, Perez A, Turner S, Jalundhwala Y, et al. Economic evaluations of clinical pharmacy services: 2006-2010. Pharmacotherapy. 2014;34(8):771-93. https://doi.org/10.1002/phar.1414
Rascati KL. Essentials of Pharmacoeconomics. 2. ed. Philadelphia: Lippincott Williams & Wilkins; 2014.
Silva EN, Silva MT, Pereira MG. Identificação, mensuração e valoração de custos em saúde. Epidemiol Serv Saude. 2016;25(2):437-9. https://doi.org/10.5123/S1679-49742016000200023
Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Relatório de Atividades 2017. Ribeirão Preto, SP: HCFMRP-USP; 2017 [cited 2018 Jul 31]. Available from: https://site.hcrp.usp.br/wp-content/uploads/2017/09/RelatoriodeAtividades_HCRP-2017.pdf
Banco Central do Brasil. Indicadores econômicos consolidados. Database. Brasília, DF; 2018 [cited 2018 Jun 27]. Available from: www.bcb.gov.br/?INDECO
Rede Brasileira de Avaliação de Tecnologias em Saúde - REBRATS. Diretrizes metodológicas: diretriz de avaliação econômica. Brasília, DF: Ministério da Saúde; 2014 [cited 2018 Jul 31]. Available from: http://rebrats.saude.gov.br/diretrizes-metodologicas
Nunes PHC, Pereira BMG, Nominato JCS, Albuquerque EM, Silva LFN, Castro IRS, et al. Intervenção farmacêutica e prevenção de eventos adversos. Rev Bras Cienc Farm. 2008;44(4):691-9. https://doi.org/10.1590/S1516-93322008000400016
Gardner KN, Diefenderfer LA, Nelson LA, Iuppa C, Elliott E, Kleinhesselink K, et al. Cost-avoidance and qualitative analysis of clinical pharmacy interventions by psychiatric pharmacy residents at state psychiatric facilities. Am J Health Syst Pharm. 2016;73(1):e46-53. https://doi.org/10.2146/ajhp150368
Bedouch P, Charpiat B, Conort O, Rose FX, Escofier L, Juste M, et al. Assessment of clinical pharmacists’ interventions in French hospitals: results of a multicenter study. Ann Pharmacother. 2008;42(7):1095-103. https://doi.org/10.1345/aph.1L045
Saokaew S, Maphanta S, Thangsomboon P. Impact of pharmacist’s interventions on cost of drug therapy in intensive care unit. Pharm Pract (Granada). 2009;7(2):81-7. https://doi.org/10.4321/s1886-36552009000200003
Whittington D. Benefits and costs of the water, sanitation and hygiene targets for the Post-2015 Development Agenda. Copenhagen (DNK): Copenhagen Consensus Center; 2015 [cited 2018 Oct 18]. Available from: http://www.pseau.org/outils/ouvrages/copenhagen_consensus_center_post_2015_consensus_water_resource_management_perspective_whittington_2015.pdf
Strand LM, Cipolle RJ, Morley PC, Frakes MJ. The impact of pharmaceutical care practice on the practitioner and the patient in the ambulatory practice setting: twenty-five years of experience. Curr Pharm Des. 2004;10(31):3987-4001. https://doi.org/10.2174/1381612043382576
Reeve E, Moriarty F, Nahas R, Turner JP, Kouladjian O’Donnell L, Hilmer SN. A narrative review of the safety concerns of deprescribing in older adults and strategies to mitigate potential harms. Expert Opin Drug Saf. 2018;17(1):39-49. https://doi.org/10.1080/14740338.2018.1397625
Bayley KB, Savitz LA, Maddalone T, Stoner SE, Hunt JS, Wells R. Evaluation of patient care interventions and recommendations by a transitional care pharmacist. Ther Clin Risk Manag. 2007;3(4):695-703.
Instituto Brasileiro de Geografia e Estatística. Pesquisa Nacional de Saúde 2013. Acesso e utilização dos serviços de saúde, acidentes e violência: Brasil, grandes regiões e unidades da federação. Rio de Janeiro: IBGE; 2015 [cited 2018 Jul 27]. Available from: https://biblioteca.ibge.gov.br/visualizacao/livros/liv94074.pdf
Gallagher J, McCarthy S, Byrne S. Economic evaluations of clinical pharmacist interventions on hospital inpatients: a systematic review of recent literature. Int J Clin Pharm. 2014;36:1101-14. https://doi.org/10.1007/s11096-014-0008-9
Bond CA, Raehl CL, Franke T. Clinical pharmacy services, hospital pharmacy staffing, and medication errors in United States hospitals. Pharmacotherapy. 2002;22(2):134-47. https://doi.org/10.1592/phco.22.3.134.33551
Youngson R, Blennerhassett M. Humanising healthcare. BMJ. 2016;355:i6262. https://doi.org/10.1136/bmj.i62
Published
Issue
Section
License
Copyright (c) 2020 Revista de Saúde Pública
This work is licensed under a Creative Commons Attribution 4.0 International License.
